MOUNJARO® 7.5mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 7.5mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 7.5mg/0.6ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 7.5mg KwikPen contains tirzepatide in a multidose injection pen designed for once-weekly administration. Typically prescribed after the 5mg maintenance dose, it provides four prefilled weekly injections to support individualized treatment progression. Patients should use the medication exactly as directed while maintaining healthy dietary habits and regular physical activity throughout therapy.

MOUNJARO® 7.5mg KwikPen delivers 7.5mg of tirzepatide — a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company — in a 0.6mL pre-filled, once-weekly subcutaneous injection. Positioned as the intermediate titration step between the 5mg and 10mg strengths, it is prescribed for adults with type 2 diabetes and eligible adults undergoing chronic weight management as an adjunct to diet and exercise. Each KwikPen contains four fixed doses intended for single-patient use [3]. Healthcare professionals looking to buy MOUNJARO® 7.5mg KwikPen online can contact the Maylips support team for product and ordering guidance.

Product Specifications

• Strength:5mg per dose (0.6mL)
• Active Substance: Tirzepatide
• Dosage Form: Solution for injection in one pre-filled KwikPen containing four doses
• Manufacturer: Eli Lilly and Company
• FDA Approval Date: 2022
• Molecular Type: Dual GIP and GLP-1 receptor agonist peptide
• Administration: Once-weekly subcutaneous injection
• Pack Size: One pre-filled KwikPen containing four weekly doses
• Package Dimensions: Width: 60mm • Height: 40mm • Length: 150mm
• Package Weight: 60g

Healthcare professionals should consult the latest prescribing information available in their region before initiating treatment or ordering the product.

MOUNJARO® 7.5mg KwikPen contains tirzepatide as its active substance — a synthetic dual incretin receptor agonist that engages both GIP and GLP-1 pathways to support glycemic control and, where locally indicated, chronic weight management. Tirzepatide is the International Nonproprietary Name (INN) for the active molecule, while MOUNJARO® is the proprietary brand name Eli Lilly and Company uses across all approved strengths. Both terms refer to the same pharmaceutical compound; the distinction lies between the generic scientific name and the commercial product presentation [3].

The 7.5mg strength is the intermediate step in the MOUNJARO® titration sequence, sitting between the 5mg and 10mg doses. It is prescribed when a patient has completed the 5mg stage and requires additional therapeutic effect before any clinical consideration of further escalation. The decision to progress to 7.5mg should be based on the patient’s individual tolerability and the degree of glycemic or weight-management response achieved at the prior dose [4].

Each KwikPen contains four pre-filled doses, each delivering 7.5mg of tirzepatide in 0.6mL, for once-weekly subcutaneous administration [3]. The fixed-dose format eliminates the need for manual preparation and supports consistent dosing, making it suitable for continued outpatient therapy under the clinical supervision of a doctor, pharmacist, or nurse. Healthcare professionals should consult current prescribing information for applicable pack sizes, storage requirements, and dispensing conditions in their region [4].

Tirzepatide is the first approved agent in its class to simultaneously activate both GIP and GLP-1 receptors via distinct binding domains within a single synthetic peptide [2]. This dual-receptor engagement sets it apart from conventional GLP-1 receptor agonists, which target only one incretin pathway, and underpins its effects on glucose regulation, body weight, and broader metabolic function.

Key pharmacological actions include:

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. These combined effects reduce fasting and postprandial blood glucose levels and support satiety in adults with type 2 diabetes [2].
• GIP receptor activation: Enhances insulin responsiveness and modulates adipose tissue metabolism. Evidence suggests that GIP receptor activity may also improve gastrointestinal tolerability relative to GLP-1 monotherapy, potentially attenuating the frequency or severity of nausea, diarrhea, and vomiting [2].
• Glucose-dependent mechanism: Because insulin secretion is triggered by elevated blood glucose concentrations, the standalone risk of hypoglycemia is comparatively low. This risk increases meaningfully when tirzepatide is co-administered with insulin or sulfonylureas, and blood sugar monitoring is required in those settings [4].

Clinical evidence from the SURPASS-2 trial demonstrates that tirzepatide produced greater reductions in HbA1c and body weight than semaglutide in adults with type 2 diabetes [2]. Data from the SURMOUNT-1 program further support its role in achieving meaningful body weight reduction among eligible adults receiving chronic weight management treatment [1]. Healthcare professionals should consult the full prescribing information for complete pharmacological data, titration schedules, and guidance on drug interactions before initiating or adjusting therapy [4].

MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, but is not intended for type 1 diabetes or diabetic ketoacidosis [4]. The 7.5mg dose is suited to patients who have completed the 5mg titration step and require escalation based on clinical response and tolerability [2].

For weight management, tirzepatide is approved under a separate brand name in the U.S., but the MOUNJARO® KwikPen is indicated for chronic weight management in international markets like the UK and EU [5]. Eligible adults in those regions typically have a BMI ≥30 kg/m², or a BMI ≥27 kg/m² with at least one weight-related comorbidity, such as obstructive sleep apnoea [5]. Weight loss may improve respiratory outcomes in these patients; this should be assessed during clinical reviews. Licensed practitioners should verify local requirements before prescribing [5].

Before escalating a patient to 7.5mg, clinicians should confirm that:

• Glycemic or weight goals were not fully achieved at 5mg.
• Prior gastrointestinal adverse reactions have been managed and are not ongoing.
• Blood sugar has been monitored, especially if combined with insulin or sulfonylureas [4].
• Obesity-related comorbidities, including obstructive sleep apnoea, are reviewed and documented.

Because MOUNJARO® must be used alongside diet and exercise, prescribers should ensure that patients maintain active lifestyle modifications, and a doctor or pharmacist should review all drug interactions and patient history before escalation [4].

MOUNJARO® 7.5mg KwikPen is administered once weekly via subcutaneous injection. Appropriate injection sites include the abdomen, upper thigh, and outer upper arm. Although the injection can be given at any time of day with or without food, administering it on the same day each week supports a consistent treatment schedule. Sites should be rotated with each dose to minimize local tissue irritation and reduce the likelihood of injection site reactions [4].

Before each use, both the pen and solution should be inspected. The solution should appear clear; if it is cloudy, discolored, or contains visible particles, the pen should not be used. A new needle must be attached for each injection, and the site should be prepared using aseptic technique. To administer, insert the needle at the prepared site, press the activation button, and hold the pen in place for approximately 10 seconds to confirm complete dose delivery. The dose window should be verified after injection, and the used needle disposed of safely [4].

If a weekly dose is missed, it may be given within four days of the originally scheduled time. If more than four days have elapsed, the missed dose should be skipped, and the regular weekly schedule resumed without doubling up. A pharmacist or nurse should reinforce correct KwikPen technique at therapy initiation and whenever the dose is changed [4]. Licensed practitioners looking to buy MOUNJARO® KwikPen wholesale can reach the Maylips support team directly for ordering guidance.

Most adverse reactions associated with MOUNJARO® are gastrointestinal (GI) and occur most frequently during dose escalation. At the 7.5mg stage, patients may have developed some tolerance, but escalation can still prompt a temporary increase in symptoms. Healthcare professionals should discuss this before progressing from 5mg and advise on dietary and hydration strategies.

Common reactions include nausea, diarrhea, vomiting, constipation, reduced appetite, and abdominal discomfort. These effects are generally mild to moderate and diminish over time. Patients must maintain adequate fluid intake to reduce the risk of dehydration-related complications [4].

Additional safety considerations include:

• Hypoglycemia: Risk is low as monotherapy due to a glucose-dependent mechanism, but increases when co-administered with insulin or sulfonylureas. Blood sugar should be monitored and concomitant doses adjusted if needed [4].
• Injection site reactions: Mild redness, swelling, or tenderness typically resolve without intervention. Rotating weekly injection sites minimizes recurrence.
• Serious events (rare): Pancreatitis, gallbladder disorders, and renal impairment secondary to dehydration require clinical vigilance. Patients should contact a healthcare professional if symptoms are severe or persistent [4].

Suspected adverse reactions should be reported via local pharmacovigilance systems. Healthcare professionals should consult full prescribing information before initiating or adjusting treatment [4].

Important Safety Notice: Tirzepatide causes thyroid C-cell tumors in rodents; human relevance is unknown. It is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [4].

MOUNJARO® 7.5mg KwikPen is a prescription-only pharmaceutical product containing tirzepatide. Eli Lilly and Company Limited holds the U.S. license, and supply is restricted to licensed medical practitioners, healthcare facilities, and authorized pharmaceutical channels in accordance with applicable national regulations [4].

Approved indications, prescribing conditions, and regulatory designations differ between jurisdictions. In the U.S., the MOUNJARO® brand name is approved for type 2 diabetes only; tirzepatide for weight management carries a separate U.S. brand designation. The MOUNJARO® KwikPen multi-dose format carries its own jurisdiction-specific indications in international markets, including the UK and EU [5]. Healthcare professionals should confirm current local prescribing information and applicable regulatory requirements before initiating, dispensing, or recommending therapy.

When buying online, licensed practitioners should review product-specific clinical requirements, jurisdiction-specific regulatory obligations, and applicable professional sourcing standards. Regulatory information is current as of the date of this publication; prescribers and dispensing professionals should verify local requirements before use.

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
3. S. Food and Drug Administration. MOUNJARO® (tirzepatide) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
4. Eli Lilly and Company. MOUNJARO® KwikPen strengths and doses. 2025. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses
5. De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes, Obesity and Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC10087310/

All content on this website is intended for informational purposes and does not constitute medical advice.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.